RT Journal
A1 Alldredge BK, Kayser SR
T1 Bending the curve toward increased use of generic drugs: Comment on “when choosing statin therapy”
JF JAMA Internal Medicine
JO JAMA Internal Medicine
YR 2013
FD February 11
VO 173
IS 3
SP 233
OP 234
DO 10.1001/jamainternmed.2013.1777
UL http://dx.doi.org/10.1001/jamainternmed.2013.1777
AB 
Despite the individual and societal benefits associated with lowering drug costs, generic drugs are underused. This is occurring even in the face of compelling evidence from bioequivalence and randomized controlled trials supporting the equivalence of generic drug products1 and efforts from payers to move patients and prescribers toward generics (eg, tiered pharmacy benefits and prior authorization for less cost-effective agents). As Green et al2 point out, the adoption of generic statins to decrease coronary heart disease risk has been slow and disappointingly incomplete, given the equivalence (in terms of clinical efficacy and safety) of generic-available and brand-only statins.